Vertex Pharmaceuticals Inc
F:VX1

Watchlist Manager
Vertex Pharmaceuticals Inc Logo
Vertex Pharmaceuticals Inc
F:VX1
Watchlist
Price: 388.2 EUR -0.23% Market Closed
Market Cap: 100.3B EUR
Section:
 

Relative Value

The Relative Value of one VX1 stock under the Base Case scenario is hidden EUR. Compared to the current market price of 388.2 EUR, Vertex Pharmaceuticals Inc is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

VX1 Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Valuation Multiples

9.8
P/S
P/S
Price to Sales
9.8
vs History
34
vs Industry
40
Median 3Y
9.9
Median 5Y
9.4
Industry
8
Forward
9.4
More Details
31.2
P/E
P/E
Price to Earnings
31.2
vs History
3
vs Industry
6
Median 3Y
25.8
Median 5Y
24.9
Industry
23.5
Forward
24.2
More Details
30.9
P/OCF
P/OCF
Price to OCF
30.9
vs History
3
vs Industry
6
Median 3Y
20.7
Median 5Y
20.7
Industry
21.9
More Details
34.6
P/FCFE
P/FCFE
Price to FCFE
34.6
vs History
3
vs Industry
5
Median 3Y
22.3
Median 5Y
22.3
Industry
24.3
More Details
6.6
P/B
P/B
Price to Book Value
6.6
vs History
25
vs Industry
12
Median 3Y
6.3
Median 5Y
6.2
Industry
3.2
More Details
9.3
EV/S
EV/S
Enterprise Value to Sales
9.3
vs History
28
vs Industry
34
Median 3Y
9.3
Median 5Y
8.4
Industry
8.1
Forward
8.9
More Details
10.7
EV/GP
EV/GP
Enterprise Value to Gross Profit
10.7
vs History
28
vs Industry
33
Median 3Y
10.8
Median 5Y
9.5
Industry
10.1
More Details
22.9
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
22.9
vs History
22
vs Industry
6
Median 3Y
21.5
Median 5Y
19.3
Industry
5.9
Forward
19.8
More Details
23.9
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
23.9
vs History
22
vs Industry
5
Median 3Y
22.4
Median 5Y
20.3
Industry
6.2
Forward
20.3
More Details
29.2
EV/OCF
EV/OCF
Enterprise Value to OCF
29.2
vs History
0
vs Industry
5
Median 3Y
18
Median 5Y
18
Industry
7.7
More Details
32.5
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
32.5
vs History
0
vs Industry
5
Median 3Y
19.1
Median 5Y
19.1
Industry
6.3
More Details
7.5
EV/IC
EV/IC
Enterprise Value to IC
7.5
vs History
69
vs Industry
19
Median 3Y
8.1
Median 5Y
8.6
Industry
5.6
More Details

Multiples Across Competitors

VX1 Competitors Multiples
Vertex Pharmaceuticals Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Vertex Pharmaceuticals Inc
F:VX1
114.8B EUR 9.8 31.2 22.9 23.9
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 766 261.7 -160 486 -194 881.2 -192 657.4
US
Abbvie Inc
NYSE:ABBV
405.3B USD 6.8 172.6 16.7 23.7
US
Amgen Inc
NASDAQ:AMGN
176.3B USD 4.9 25.2 18.2 18.2
US
Gilead Sciences Inc
NASDAQ:GILD
151B USD 5.2 18.6 12.5 12.5
US
Epizyme Inc
F:EPE
94.1B EUR 2 086.4 -532.4 -579.7 -564.3
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
81.7B USD 5.7 17.9 17 19.3
AU
CSL Ltd
ASX:CSL
83.3B AUD 3.6 18.6 12.5 15.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
52.7B USD 16.4 1 210.6 163.2 198
NL
argenx SE
XBRU:ARGX
44.3B EUR 14.4 33.9 58.5 60.1
US
Seagen Inc
F:SGT
39.3B EUR 20.1 -61.6 -66.4 -59.9
P/S Multiple
Revenue Growth P/S to Growth
US
Vertex Pharmaceuticals Inc
F:VX1
Average P/S: 3 069 857.7
9.8
10%
1
FR
Pharnext SCA
OTC:PNEXF
33 766 261.7
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.8
9%
0.8
US
Amgen Inc
NASDAQ:AMGN
4.9
5%
1
US
Gilead Sciences Inc
NASDAQ:GILD
5.2
4%
1.3
US
E
Epizyme Inc
F:EPE
2 086.4
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.7
6%
1
AU
CSL Ltd
ASX:CSL
3.6
5%
0.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
16.4
46%
0.4
NL
argenx SE
XBRU:ARGX
14.4
49%
0.3
US
S
Seagen Inc
F:SGT
20.1
30%
0.7
P/E Multiple
Earnings Growth PEG
US
Vertex Pharmaceuticals Inc
F:VX1
Average P/E: 191.1
31.2
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 486 N/A N/A
US
Abbvie Inc
NYSE:ABBV
172.6
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
25.2
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
18.6
190%
0.1
US
E
Epizyme Inc
F:EPE
Negative Multiple: -532.4 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.9
10%
1.8
AU
CSL Ltd
ASX:CSL
18.6
11%
1.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 210.6
N/A N/A
NL
argenx SE
XBRU:ARGX
33.9
40%
0.8
US
S
Seagen Inc
F:SGT
Negative Multiple: -61.6 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Vertex Pharmaceuticals Inc
F:VX1
Average EV/EBITDA: 40.2
22.9
16%
1.4
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 881.2 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.7
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
18.2
11%
1.7
US
Gilead Sciences Inc
NASDAQ:GILD
12.5
7%
1.8
US
E
Epizyme Inc
F:EPE
Negative Multiple: -579.7 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17
11%
1.5
AU
CSL Ltd
ASX:CSL
12.5
8%
1.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
163.2
N/A N/A
NL
argenx SE
XBRU:ARGX
58.5
810%
0.1
US
S
Seagen Inc
F:SGT
Negative Multiple: -66.4 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Vertex Pharmaceuticals Inc
F:VX1
Average EV/EBIT: 46.4
23.9
16%
1.5
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -192 657.4 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.7
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
18.2
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.5
12%
1
US
E
Epizyme Inc
F:EPE
Negative Multiple: -564.3 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
19.3
13%
1.5
AU
CSL Ltd
ASX:CSL
15.7
11%
1.4
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
198
N/A N/A
NL
argenx SE
XBRU:ARGX
60.1
N/A N/A
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.9 N/A N/A

See Also

Summary
VX1 intrinsic value, competitors valuation, and company profile.
DCF Valuation
VX1 stock valuation using Discount Cash Flow valuation method.
Relative Valuation
VX1 stock valuation using valuation multiples.
Wall Street Estimates
VX1 price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
VX1 stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 307,100+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.